echemi logo
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Urinary System > Encouraging results from 2022 AACR maveropepimut-S, intermittent low-dose cyclophosphamide combined with pembrolizumab in advanced, metastatic bladder cancer

    Encouraging results from 2022 AACR maveropepimut-S, intermittent low-dose cyclophosphamide combined with pembrolizumab in advanced, metastatic bladder cancer

    • Last Update: 2022-06-17
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit

    Introduction The 2022 American Association for Cancer Research Annual Meeting (AACR) will be held online from 4.
    13 local time


    As one of the largest cancer research conferences in the world, AACR brings together oncology research and clinical progress from around the world

    Safety, preliminary efficacy, and efficacy of the combination of maveropepimut-S (MVP-S), intermittent low-dose cyclophosphamide, and pembrolizumab in patients with advanced, metastatic bladder cancer The academic analysis data was announced at this conference, let's take a look

    1 Background MVP-S is a novel immunotherapy drug that can induce CD8 T cells to specifically respond to the tumor antigen survivin, and eliminate survivn-expressing tumor cells through an immune response

    Previous clinical studies have confirmed that MVP-S and intermittent low-dose cyclophosphamide (CPA) can produce confirmed clinical remission (partial and complete remission according to RECISTv1.
    1 criteria) and induce stable, durable, Survivin-specific CD8 T cell responses


    In addition, the combination regimen of MVP-S with pembrolizumab was well tolerated in both solid tumors and lymphomas

    This phase II study was designed to investigate the safety and efficacy of this combination regimen in patients with advanced metastatic bladder cancer (regardless of whether the patients were previously treated with an immune checkpoint inhibitor)

    Figure 1 Mechanism of action of MVP-S drugs 2 Results 17 subjects received the combination therapy of MVP-S, intermittent low-dose cyclophosphamide and pembrolizumab

    The mean number of previous treatment lines was 3, and 13 (76.
    4%) subjects had received anti-PD1/L1 therapy


    Seven subjects had disease progression on or after anti-PD1/L1 as the last line of therapy prior to inclusion in this study

    Figure 2 Patient demographics 5 of the 17 subjects responded, 3 achieved PR (unconfirmed) and 2 achieved CR (confirmed)

    Three of the five responders (including two in CR) had prior disease progression on anti-PD1/L1 therapy

    Long-term clinical benefit of the combination regimen has been observed in several subjects (one subject was thrown off treatment after 17 months), along with increased numbers of survivin-specific T cells in peripheral blood

    Figure 3 Patient response The combination regimen was well tolerated, with most adverse events of grade 1 or 2

    Figure 4 Treatment-Related Adverse Events 3 Conclusions Preliminary data suggest that MVP-S/CPA and pembrolizumab is a well-tolerated combination regimen that has shown promise in the treatment of patients with advanced or metastatic bladder cancer Encouraging clinical activity, even in patients previously treated with anti-PD-1/L1

    The follow-up results of the study are worth looking forward to

    Reference: Olivier Rixe, Vincent Castonguay, Henry Conter et al.
    Safety, preliminary efficacy and pharmacodynamic (PD) analysis of maveropepimut-S, intermittent low-dose cyclophosphamide and pembrolizumab in patients with advanced, metastatic bladder cancer.
    2022 AACR Meeting.
    CT035 .
    Edit: LR Reviewer: XY Execution: LR
    This article is an English version of an article which is originally in the Chinese language on and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to with relevant evidence.